Tessera
Folgen

Chetan Shenoy

@cshenoy.bsky.social

Cardiologist and researcher, in cardiovascular magnetic resonance imaging, at the University of Minnesota

58 Posts844 Follower446 Folgt
TCTMD@tctmd.bsky.social · last yr.

“CMR phenotyping can be used immediately in clinical practice to identify patients with suspected cardiac sarcoidosis who would benefit from a primary prevention ICD," said Chetan Shenoy, MD. Read more about how this can prevent life-threatening ventricular arrhythmias: www.tctmd.com/news/cmr-may...

CMR May Improve Assessment of ICD Need in Cardiac Sarcoidosis

The imaging was better than societal recommendations at discriminating long-term risk of ventricular arrhythmias.

tctmd.com

Chetan Shenoy@cshenoy.bsky.social · last yr.

Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement academic.oup.com/eurheartj/ad... #Cardiosky #WhyCMR #Epeeps #Medsky

In patients with suspected cardiac sarcoidosis, CMR phenotyping showed greater discriminative accuracy than societal recommendations for predicting fatal or life-threatening ventricular arrhythmias, suggesting that it may be more effective at identifying candidates for primary prevention ICDs.
Chetan Shenoy@cshenoy.bsky.social · last yr.

academic.oup.com/eurheartj/ad... @escardio.bsky.social #Cardiosky #WhyCMR #Epeeps #Medsky Please DM me if you would like a full-text PDF of the paper!

Chetan Shenoy@cshenoy.bsky.social · last yr.

pmc.ncbi.nlm.nih.gov/articles/PMC... #HCM #CardioSky #Cardiomyopathy

Comparisons against baseline within randomised groups are often used and can be highly misleading

In randomised trials, rather than comparing randomised groups directly some researchers carry out a significance test comparing a baseline with a final measurement separately in each group. We give se...

pmc.ncbi.nlm.nih.gov

B Grrl@bgrrl.bsky.social · last yr.

In patients with non-obstructive HCM, there was a reduction in myocardial T1 time with Eplerenone, consistent with a reduction in diffuse myocardial fibrosis. #HCM #CardioSky #Cardiomyopathy

Chetan Shenoy@cshenoy.bsky.social · 2y ago

This paper reports the coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy in 5 patients. heart.bmj.com/content/earl... #CardioSky #MedSky

Coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy-associated genetic variants: a multicentre case-control study

Background Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmo...

heart.bmj.com

Sarah Hudson@sarahhudsonuk.bsky.social · 2y ago

Great thread on LV thrombus and embolism risk - especially if RWMA I discuss lifelong anti coagulation with my pts even if it looks resolved on echo, good to have some data to help back this up 👇

Chetan Shenoy@cshenoy.bsky.social · 2y ago

In 2019, we wrote a paper showing that patients with left ventricular thrombus have a long-term risk of embolism, extending to at least 8 years. We were puzzled by the finding… #CardioSky www.ahajournals.org/doi/10.1161/...

Figure 2 from the paper. Incidence of embolism in left ventricular (LV) thrombus patients compared with matched non-LV thrombus patients. Kaplan-Meier curves demonstrate the cumulative incidence of the composite embolic end point in the LV thrombus (in red) and in the matched non-LV thrombus (in blue) groups. Note the significant difference in the cumulative incidence of embolic events between the 2 groups.
Lars Mølgaard Saxhaug@load-dependent.eurosky.social · 2y ago

It’s great that journals are coming over here, but what I have really missed after my departure from Twitter 2 years ago is this, the authors themselves presenting their works and discussing it with peers. #cardiosky #medsky #emimcc

Chetan Shenoy@cshenoy.bsky.social · 2y ago

In 2019, we wrote a paper showing that patients with left ventricular thrombus have a long-term risk of embolism, extending to at least 8 years. We were puzzled by the finding… #CardioSky www.ahajournals.org/doi/10.1161/...

Figure 2 from the paper. Incidence of embolism in left ventricular (LV) thrombus patients compared with matched non-LV thrombus patients. Kaplan-Meier curves demonstrate the cumulative incidence of the composite embolic end point in the LV thrombus (in red) and in the matched non-LV thrombus (in blue) groups. Note the significant difference in the cumulative incidence of embolic events between the 2 groups.
Luke Cieslik 🇺🇦@lukekc.bsky.social · 2y ago

Thanks. So for example - post anterior infarct, persisting WMA on CMR at 6 months despite OMT (but improvement in overall LVEF). Lifelong anticoagulation or would you reimage at a further interval (I.e. 12 months) to look for improvement in wall motion abnormality?

Luke Cieslik 🇺🇦@lukekc.bsky.social · 2y ago

Great work Chetan. An important area where as a community we need to get better at managing - particularly in the post (anterior) STEMI space. What are your thoughts on stopping anticoagulation at 3 or 6 months post MI with persisting wall motion defects but resolved thrombus?

Florian Zores@fzores.eurosky.social · 2y ago

Congratulations for this work! Do you have data for patients with CMR and echo to evaluate the discrepancy? We need a well designed RCT to answer this important although infrequent question. And to assess the effectiveness of DOAC in these cases